MOLOGEN AG adapts executive board structure to future growth

Company expands board to three members, appoints new

chief financial officer

MOLOGEN AG (ISIN DE0006637200) today announced that it has optimized its executive board structure to meet the requirements of future corporate growth. The company will expand its executive board from two to three members. MOLOGEN will also appoint a new chief financial officer. Effective September 1, 2005, the supervisory board of MOLOGEN will appoint Dirk Simon new chief financial officer. Simon will succeed Matthias Reichel, who resigned amicably in order to pursue a new career challenge. The executive board and the supervisory board thank Mr. Reichel for his work in the past seven years.

Effective August 1, 2005, Dr. Matthias Schroff will be appointed to the executive board of MOLOGEN. He will serve as chief operating officer. The enlargement of the executive board reflects the expected expansion of the company's business activities in the next years.

After studying computer science, Dirk Simon worked for auditing firms for a number of years before entering the biotechnology and pharmaceutical industry. After a stint with Hoechst Schering Agrevo GmbH, he held leading commercial positions with the Merckle Group. His work focused on controlling in research and development and on business development.

Dr. Matthias Schroff, the new COO, is a renowned scientist and long-standing employee of MOLOGEN. Dr. Schroff is the co-inventor of key MOLOGEN patents. A graduate biochemist, Dr. Schroff first served as senior scientist and managing director of MOLOGEN GmbH. He is currently the head of product development and holder of a general commercial power of attorney ("Prokurist") at MOLOGEN AG. He has been working closely with MOLOGEN's CEO, Prof. Dr. Burghardt Wittig, since university.

About MOLOGEN

MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview